With a higher level of PCR excellence from Cepheid, clinicians and their patients have LESS uncertainty and MORE confidence.

Cepheid’s menu of 20+ Health Canada approved tests run on the GeneXpert® family of systems to provide accurate, high-quality Real-Time PCR results when and where you need them most. 

Improved outcomes* with PCR testing

Cepheid's tests enable improved clinical outcomes, operational efficiencies, and patient experience across the continuum of care. That's the PCRplus advantage.

 

 

Clinical

 

 

Operational

 

Financial

Healthcare-Associated Infections

Virus
 
Bed
 
Finance

MRSA
C. difficile
Carba-R
VRE

 

69-85% decrease
in infection rate1

 

 

 

 

Shortened length of stay
in hospital by 2.5 days3
 

 

33% decrease 

in isolation days2

Respiratory Infections

Target
 
Mask
 
Finance

Flu
RSV
Strep A
COVID-19

 

18% increase
in accurate test results reduced empiric treatment3

 

 

 

 

387-day decrease
in unnecessary droplet precautions4

 

 

 

 

$400K savings
in bed costs and Tamiflu® usage4

 

 

Women's & Sexual Health

Bottle
 
Clock
 
Finance

Chlamydia
Gonorrhea
Trichomoniasis
GBS

 

12.5% increase
in appropriate initial treatment5

 

 

 

 

2 hours per day reduction
in staff time spent on phone calls with anxious patients6

 

 

 

 

$37K savings
in additional testing, antimicrobial utilization, and ED readmission5

 

GeneXpert systems and GeneXpert Infinity systems can run our full menu of moderate complexity tests for respiratory diseases, women's and sexual health, healthcare-associated infections, and oncology. 

A test can change a life. That's why we're committed to a higher level of PCR exellence. One that combines speed, accuracy, and flexibility to deliver unmatched results.

Speed, plus
Accuracy, plus
Flexibility

That's the PCRplus advantage.
From Cepheid.

 

Tests

With over 20 Health Canada-approved tests, Cepheid is the ideal diagnostic Real-Time PCR partner for improved clinical decision-making and patient care.

Visit our Education Center for more educational webinars and videos.

Visit Now

 

FAQs

The PCRplus advantage delivers a higher level of PCR excellence by bringing together:

  • Accurate results that clinicians and patients can rely on.

  • Speed and efficiency to deliver on-demand answers WHEN they are needed most.

  • A flexible delivery platform - like the GeneXpert® system and Xpert® test cartridges - that can deliver those results WHERE they are needed, from the lab to the point of care.

  • Quality of test design - a proven track record of delivering quality across a broad menu of test products. Experience matters.

  • Simplicity - a solution that is easy to learn, adopt, and operate across a variety of settings and users.

GeneXpert systems are available in a two, four, 16, 48, or 80-module configuration. All GeneXpert systems have our proven GeneXpert module at their analytic heart, and use the same patented cartridge technology for every Xpert test.

References

IVD. In Vitro Diagnostic Medical Device. May not be available in all countries.

1. Cepheid. Ephraim McDowell Regional Medical Center improves adherence to optimized testing protocols for Clostridium difficile resulting in lower C. difficile rates and decreased patient time in isolation. (0664-03) [Impact Brief] http://cepheidevents.com/Case-Studies/Cepheid_Ephraim%20McDowell_Case%20Study_US_0664-03.pdf
2. Cepheid. Leading-edge molecular testing drives improved process and enhanced patient care. (0566-01) [Impact Brief] http://cepheidevents.com/Case-Studies/Wenatchee%20Impact%20Brief%200566-01.pdf
3. Cepheid. Millard Henry Clinic (MHC) improves treatment accuracy through the use of Xpert® Xpress Flu/RSV and antimicrobial stewardship while maintaining efficient patient flow during a very busy flu season. (0716-01) [Impact Brief] https://p.widencdn.net/fhd4k4/Cepheid-Millard-Henry-Clinic-Case-Study-US-IVD-0716-English
4. Cepheid. Einstein Medical Center Montgomery sees significant reduction in oseltamivir (Tamiflu®) usage and improved length of stay through the use of real-time PCR testing with Xpert® Flu/RSV XC. (0724-02.A) [Impact Brief] https://p.widencdn.net/qvoang/Cepheid-Einstein-Medical-Center-Case-Study-US-IVD-0724-English
5. Cepheid. Mercy Health Saint Mary’s in Grand Rapids, MI reduces time to result and improves treatment accuracy through the use of Xpert® CT/NG and antimicrobial stewardship (0629-01) [Impact Brief] http://cepheidevents.com/Case-Studies/Cepheid_Mercy_Health_Case_Study_US_0629_01.pdf
6. Cepheid. Women’s Health Group reduces time to result and improves treatment accuracy through the use of Xpert® CT/NG and antimicrobial stewardship (0700-01) [Impact Brief] http://cepheidevents.com/Case- Studies/ Cepheid_The_Womens_Health_Group_Case_Study_US_0700_01.pdf

* Projections and realized results are specific to the institution where they were obtained and may not reflect the results achievable at other institutions.
^CLIA waived tests available for use on the GeneXpert Xpress system.
# With early assay termination (EAT) for positive results. Full tests runtimes are as follows: Xpert Xpress Flu is 30 minutes, Xpert Xpress SARS-CoV-2 is approximately 45 minutes, Xpert Xpress Strep A is 24 minutes, Xpert TV is 70 minutes, Xpert C. difficile is 43 minutes, Xpert Xpress CoV-2/Flu/RSV plus is 36 minutes.
†For positive Flu only or RSV only. Reporting negatives and combined reporting in 30 minutes.
‡ These tests have not been FDA cleared or approved. These tests have been authorized by FDA under an EUA for use by authorizedlaboratories; XpertXpress SARS-CoV-2 has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. XpertXpress SARS-CoV-2/Flu/RSV plushas been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, InfuenzaA, InfuenzaB, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Supported on GeneXpert and Infinity Systems in laboratories certified under CLIA to perform high- and moderate-complexity tests and the GeneXpert Xpress system in CLIA waived settings.
**With early assay termination for positives when running SARS-CoV-2 only. Full run time is 36 min.

Request Information

In submitting this form, you agree to be contacted by Cepheid to receive information on products, goods, and services, which may include similar products, goods, or services from our affiliates. Consent may be withdrawn at any time. For additional information about how we handle your personal data, please review our online privacy policy.